Comparative Pharmacology
Head-to-head clinical analysis: TETRACHEL versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACHEL versus TETRAMED.
TETRACHEL vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
100 mg orally every 12 hours
None Documented
None Documented
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic